# Antibody-Drug Conjugates for Multiple Myeloma — An Interview with Dr Douglas W Sborov

Page: https://stenobird.com/podcast/hematologic-oncology-update-916423/antibody-drug-conjugates-for-multiple-myeloma-an-interview-with-dr-douglas-w-sborov
Text version: https://stenobird.com/podcast/hematologic-oncology-update-916423/antibody-drug-conjugates-for-multiple-myeloma-an-interview-with-dr-douglas-w-sborov.md
Podcast: [Hematologic Oncology Update](https://stenobird.com/podcast/hematologic-oncology-update-916423)
Published: 2026-09-23T18:00:00+00:00
Episode link: https://hematologic-oncology.captivate.fm/episode/6152-oncologytodayadcsmm26
Audio file: https://dts.podtrac.com/redirect.mp3/episodes.captivate.fm/episode/4e784545-c3b6-4dd0-b0a7-5abf63fc1a5f.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/hematologic-oncology-update-916423/episodes/antibody-drug-conjugates-for-multiple-myeloma-an-interview-with-dr-douglas-w-sborov
Duration seconds: 2981

## Resource

Featuring an interview with Dr Douglas W Sborov, including the following topics: DREAMM-2 trial outcomes and clinical development of antibody-drug conjugates for multiple myeloma (MM); mechanism of action of belantamab mafodotin (belamaf) and predictors of response to treatment (0:00) Perspectives on findings from the Phase III DREAMM-7 trial of belamaf combined with bortezomib/dexamethasone for relapsed/refractory MM (4:26) Progression-free survival estimates with current quadruplet induction and maintenance regimens for newly diagnosed MM (6:36) Phase I DREAMM-9 trial and ongoing evaluation of belamaf in the up-front setting (11:48) Potential integration of belamaf into the relapsed/refractory and newly diagnosed MM treatment settings (16:00) Prevention and management of ophthalmic events related to treatment with belamaf (21:27) Case: A man in his mid 60s with multiregimen-recurrent MM receives single-agent belamaf (27:49) Case: A woman in her early 70s with recurrent t(11;14) MM and disease progression on single-agent belamaf experiences a sustained response to talquetamab (33:27) Case: A man in his early 70s with heavily pretreated MM receives belamaf with bortezomib (39:53) CME information and select publications

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/hematologic-oncology-update-916423/episodes/antibody-drug-conjugates-for-multiple-myeloma-an-interview-with-dr-douglas-w-sborov/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/hematologic-oncology-update-916423/antibody-drug-conjugates-for-multiple-myeloma-an-interview-with-dr-douglas-w-sborov.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.